Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1483)	8/10/2007 12:31:57 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

KOSN Is up 14% on moderate volume of 55,700 bigcharts.marketwatch.com It announced on Monday that PFE has started a PI of motilin receptor agonist PF-04548043 (KOS-2187)for treatment of GERD. According to the agreement between PFE & KOSN,this product has a potential value of $250M & royalties on worldwide sales. According to KOSN's CEO, the company has several products in clinical programs: KOS-2187 (which is now PF-0454843) KOS-953 which is being tested in combination with bortezomib (Velcade) in patients with MM & is also tried in MM as monotherapy & in HER2-positive metastatic breast Ca in combination with Herceptin (trastuzumab), & as monotherapy in metastatic melanoma. Intravenous & oral formulations of alvespimycin (KOS-1022) are in PI in hematologic cancers & in HER2-positive metastatic breast Ca. KOS-1584 is in PI in patients with solid tumors & is partnered with Roche. It seems the stock could easily test the $6 level.<g> bigcharts.marketwatch.com Bernard